Press

Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

Oct 6 • 2 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that CEO Eric Weisblum will present and host investor meetings at the 7th Annual Dawson James Small Cap Growth Conference being held Wednesday, October 12, 2022, at the Wyndham Grand Hotel in Jupiter, Florida. Presentation: The…

Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

Oct 6 • 4 min read

Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a leading Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is applauding the government of Alberta’s decision to regulate some psychedelics for therapeutic use in the province. The proposed framework as…

Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial

Oct 6 • 3 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc, today announced that the Company has completed the CMC package to…

Creso Pharma Unit Completes Enrollment for Phase 2 Psychedelic Trial

Oct 6 • 1 min read

Creso Pharma (ASX:CPH) Canadian subsidiary, Halucenex, completed the enrollment of patients for its phase 2 trial investigating the use of the psychedelic drug psilocybin in patients with treatment-resistant post-traumatic stress disorder. The study, slated to start on Oct. 12, recruited 20 patients with PTSD who are also afflicted with other mental health conditions, the medical…

Atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

Oct 5 • 3 min read

atai Life Sciences N.V. (Nasdaq: ATAI), which is developing VLS-01, a form of N,N-dimethyltryptamine (DMT) for the treatment of treatment-resistant depression (TRD), announced today the dosing of the first subject in their Phase 1 SAD trial of VLS-01. The trial is a randomized, double-blind, placebo-controlled study designed to evaluate the relative bioavailability of buccal versus IV…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441